Developing Innovative Therapies to Change Lives
Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of innovative, de-risked drug candidates in disease areas with significant unmet needs. Melior leverages its proprietary drug screening technology to identify new and patentable uses for drugs that have been developed for other indications and that have significant clinical safety history.
Our leading drug candidates are in early to mid-stage clinical development for Type 2 Diabetes, Nonalcoholic Steatohepatitis (NASH), Parkinson’s Disease and Sleep Disorders.LEARN MORE
Expanding the Pipeline
Melior’s pipeline includes, (1) Tolimidone, a novel lyn kinase activator, currently in development for Type 2 Diabetes and NASH, and (2) Mesocarb, a highly selective and well tolerated dopamine reuptake inhibitor, in development for Parkinson’s Disease and Sleep Disorders.LEARN MORE
A New Approach to Treat Diabetes
Tolimidone is a lyn kinase activator, with insulin sensitizing and lipid regulation effects, currently in Phase 2b clinical development for Type II Diabetes.
Tolimidone is also in early stage clinical development for NASH.LEARN MORE
Mesocarb is a highly selective and well tolerated dopamine reuptake inhibitor, in development for Parkinson’s Disease and Sleep Disorders. The product was previously marketed for different uses outside the US and has extensive safety data.LEARN MORE